[HTML][HTML] Anti-spike mucosal IgA protection against SARS-CoV-2 omicron infection
S Havervall, U Marking, J Svensson… - … England Journal of …, 2022 - Mass Medical Soc
New England Journal of Medicine, 2022•Mass Medical Soc
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection | NEJM Skip to main
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to
become a physician, build your knowledge, lead a health care organization, and advance your
career with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
content NEJM Group Follow Us Facebook Twitter Instagram YouTube LinkedIn Prepare to
become a physician, build your knowledge, lead a health care organization, and advance your
career with NEJM Group information and services. NEJM Evidence NEW! A digital journal for
innovative original research and fresh, bold ideas in clinical trial design and clinical
decision-making. NEJM Catalyst NEW! Peer-reviewed journal featuring in-depth articles to …
Protection against Omicron by Mucosal IgA Antibodies
In this study, SARS-CoV-2 infection before vaccination was found to elicit mucosal IgA, which protects against infection. Vaccines inducing mucosal immunity may be important for preventing infection.
The New England Journal Of Medicine